Phagocytosis

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheime

Retrieved on: 
Friday, March 1, 2024

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.
  • NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
  • Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
  • More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

Retrieved on: 
Thursday, January 4, 2024

SHANGHAI and WARREN, N.J., Jan. 3, 2024 /PRNewswire/ -- Laekna (2105.HK), a clinical-stage biotechnology company, today announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah. The presentation will showcase a novel antibody-based aHSC depletion discovery platform and introduce preclinical anti-fibrosis data of a bi-functional NK-aHSC engager candidates derived from this platform.

Key Points: 
  • Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis.
  • This platform enables Laekna to continually discover and develop the next generation therapeutics against liver fibrosis and potentially other types of fibrotic diseases.
  • "Liver fibrosis, metabolic diseases, and cancer are the three major indications that Laekna aims to tackle.
  • In vivo, antibodies with enhanced effector function showed significant anti-fibrotic effects in two different liver fibrosis animal models.

Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager

Retrieved on: 
Thursday, December 28, 2023

Elpiscience Biopharma, Ltd. (Chairman and CEO: Darren Ji, MD, Ph.D., “Elpiscience”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program.

Key Points: 
  • Elpiscience Biopharma, Ltd. (Chairman and CEO: Darren Ji, MD, Ph.D., “Elpiscience”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program.
  • Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration.
  • If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture and commercialize the products for each program.
  • 2 Astellas’ R&D strategy: Astellas has established a Focus Area Approach for its research and development strategy.

Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager

Retrieved on: 
Thursday, December 28, 2023

Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration.

Key Points: 
  • Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration.
  • If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture and commercialize the products for each program.
  • Their Bispecific Macrophage Engager Platform (BiME®) is anti-tumor associated antigen (TAA) and anti-signal-regulatory protein α (SIRPα) bispecific antibody-based platform to activate Tumor Associated Macrophage (TAM) phagocytosis killing towards specific TAA expressing tumor cells.
  • 2 Astellas' R&D strategy: Astellas has established a Focus Area Approach for its research and development strategy.

Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023

Retrieved on: 
Thursday, November 9, 2023

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).
  • “Neuroscience is one of the most complex areas of drug discovery,” Antti Nurmi, PhD, MSc, Regional General Manager, Europe, Charles River.
  • These innovations will ultimately accelerate success in this critical field of drug development.”
    Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders.
  • Additionally, experts will be available at Booth #1717 for meetings with those interested in discussing neuroscience research and drug discovery.

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

Retrieved on: 
Monday, October 30, 2023

Boca Raton, Florida, Oct. 30, 2023 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4.

Key Points: 
  • INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).
  • The poster entitled “INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages,” shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP.
  • INB03 downregulates SIRPα expression to eliminate the “don’t eat me signal” and promote ADCP.
  • INB03 neutralizes sTNF, repolarizing tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression.

Dren Bio Strengthens Leadership Team with Appointment of Amit Mehta, Ph.D., as Chief Operating Officer and Chief Business Officer

Retrieved on: 
Monday, October 30, 2023

Dren Bio, Inc. (“Dren Bio” or the “Company”) a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune and other serious diseases, today announced the expansion of its leadership team with the appointment of Amit Mehta, Ph.D., as the Company’s Chief Operating Officer and Chief Business Officer.

Key Points: 
  • Dren Bio, Inc. (“Dren Bio” or the “Company”) a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune and other serious diseases, today announced the expansion of its leadership team with the appointment of Amit Mehta, Ph.D., as the Company’s Chief Operating Officer and Chief Business Officer.
  • Dr. Mehta will be responsible for business development efforts, corporate strategy and leading the operational advancement and expansion of Dren Bio’s pipeline.
  • During his 18-year tenure at Genentech, Dr. Mehta held roles of increasing responsibility that spanned process development, manufacturing, strategy and business development.
  • “We are thrilled to welcome Amit as the newest member of Dren Bio’s leadership team,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio.

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

Retrieved on: 
Sunday, October 15, 2023

CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.

Key Points: 
  • CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.
  • The data are the first to show that GDF-15 has an inhibitory effect on the activation of M1 macrophages.
  • These specific myeloid lineage immune cells are central to the initiation of immune responses, including the secretion of pro-inflammatory cytokines and chemokines, presentation of antigens as well as direct antitumor cytotoxicity.
  • Overall, the results indicate that GDF-15 counteracts myeloid immune cell activation, supporting the generation of an immune-evasive tumor microenvironment, an important feature in therapy resistance.

What happens in our body when we encounter and fight off a virus like the flu, SARS-CoV-2 or RSV?

Retrieved on: 
Friday, July 28, 2023

They spread from person to person through respiratory droplets when someone coughs, sneezes, or talks and can cause death in serious cases.

Key Points: 
  • They spread from person to person through respiratory droplets when someone coughs, sneezes, or talks and can cause death in serious cases.
  • But what happens in our body when we first encounter these viruses?

First line of defence

    • When we encounter respiratory viruses, the first line of defence is the physical and chemical barriers in our nose, upper airways, and lungs.
    • Our defence also includes our behaviours such as coughing or sneezing.

Patrolling for potential invaders

    • The cells of innate immunity act like a patrol system, searching for any invaders.
    • These innate cells patrol almost every part of our body, from our skin to our nose, lungs and even internal organs.
    • In the meantime, natural killer cells, aptly named, attack infected cells, and stop viruses from multiplying and invading our body further.
    • At this stage, our immune system is fighting a war against viruses and the result can cause inflammation, fevers, coughs and congestion.

Launching a specific attack

    • As the innate immune response begins, another branch of the immune system called the adaptive immune system is activated.
    • The adaptive immune system is more specific than the innate immune system, and it decides on the correct tools and strategy to fight off the viral invaders.
    • B cells produce antibodies, which are proteins that can bind to viruses, neutralise them, and mark them for destruction by other immune cells.
    • B cells are a critical part of memory in our immune system.

Neutralising the threat

    • As the infection subsides, symptoms gradually improve, and we begin to feel better and to recover.
    • Some respiratory viruses, like rhinoviruses which cause the common cold, may cause relatively mild symptoms and a quick recovery.
    • Others, like the flu, SARS-CoV-2 or severe cases of RSV, may lead to more severe symptoms and a longer recovery time.